TWI249404B - Apoptotic entities for use in treatment of T-cell-mediated and inflammatory disorders - Google Patents

Apoptotic entities for use in treatment of T-cell-mediated and inflammatory disorders Download PDF

Info

Publication number
TWI249404B
TWI249404B TW90113342A TW90113342A TWI249404B TW I249404 B TWI249404 B TW I249404B TW 90113342 A TW90113342 A TW 90113342A TW 90113342 A TW90113342 A TW 90113342A TW I249404 B TWI249404 B TW I249404B
Authority
TW
Taiwan
Prior art keywords
cells
cell
apoptotic
pharmaceutical composition
patient
Prior art date
Application number
TW90113342A
Other languages
English (en)
Chinese (zh)
Inventor
Anthony E Bolton
Arkady Mandel
Daniel Sauder
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Application granted granted Critical
Publication of TWI249404B publication Critical patent/TWI249404B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
TW90113342A 2000-05-25 2001-06-01 Apoptotic entities for use in treatment of T-cell-mediated and inflammatory disorders TWI249404B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2309518 CA2309518A1 (en) 2000-05-25 2000-05-25 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders

Publications (1)

Publication Number Publication Date
TWI249404B true TWI249404B (en) 2006-02-21

Family

ID=4166254

Family Applications (1)

Application Number Title Priority Date Filing Date
TW90113342A TWI249404B (en) 2000-05-25 2001-06-01 Apoptotic entities for use in treatment of T-cell-mediated and inflammatory disorders

Country Status (11)

Country Link
US (1) US20020051771A1 (enExample)
EP (2) EP1289534B1 (enExample)
JP (1) JP2003534281A (enExample)
AT (1) ATE311191T1 (enExample)
AU (1) AU2001261986A1 (enExample)
CA (1) CA2309518A1 (enExample)
DE (1) DE60115432T2 (enExample)
DK (1) DK1289534T3 (enExample)
ES (1) ES2254424T3 (enExample)
TW (1) TWI249404B (enExample)
WO (1) WO2001089536A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2327631A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Inflammatory cytokine secretion inhibition
US7727523B2 (en) * 2001-08-13 2010-06-01 Yale University Method for suppressing immune system response to transplanted tissue or cells
CA2457015C (en) * 2001-08-13 2012-03-13 Richard L. Edelson Method for inducing selectively suppressed immune response
BR0214571A (pt) * 2001-11-29 2006-05-30 Therakos Inc métodos para pré-tratar um indivìduo com fotoférese extracorporal e/ou células apoptóticas
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
CN105102612B (zh) * 2012-12-06 2020-11-17 恩立夫克治疗有限责任公司 治疗性凋亡细胞制剂、其制备方法以及其用途
WO2017141243A1 (en) * 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) * 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN107708811B (zh) 2015-04-21 2021-04-30 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
WO2023209709A1 (en) * 2022-04-27 2023-11-02 Enlivex Therapeutics Rdo Ltd Apoptotic cell - chemotherapy combination therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
BR0214571A (pt) * 2001-11-29 2006-05-30 Therakos Inc métodos para pré-tratar um indivìduo com fotoférese extracorporal e/ou células apoptóticas

Also Published As

Publication number Publication date
WO2001089536A2 (en) 2001-11-29
AU2001261986A1 (en) 2001-12-03
ES2254424T3 (es) 2006-06-16
HK1055079A1 (en) 2003-12-24
EP1289534B1 (en) 2005-11-30
DK1289534T3 (da) 2006-03-20
DE60115432D1 (de) 2006-01-05
US20020051771A1 (en) 2002-05-02
EP1669081A1 (en) 2006-06-14
DE60115432T2 (de) 2006-08-24
ATE311191T1 (de) 2005-12-15
WO2001089536A3 (en) 2002-08-01
JP2003534281A (ja) 2003-11-18
CA2309518A1 (en) 2001-11-25
EP1289534A2 (en) 2003-03-12

Similar Documents

Publication Publication Date Title
TWI249404B (en) Apoptotic entities for use in treatment of T-cell-mediated and inflammatory disorders
Bell et al. The extracellular release of HMGB1 during apoptotic cell death
Chen et al. Glycyrrhizin ameliorates experimental colitis through attenuating interleukin-17-producing T cell responses via regulating antigen-presenting cells
Sonoda et al. Long-term survival of corneal allografts is dependent on intact CD1d-reactive NKT cells
US20080131416A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
JP2002543140A (ja) 免疫系の標的刺激へのフィランサスの使用
Cullen et al. Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation
Rentzsch et al. Specific protein antigen delivery to human langerhans cells in intact skin
Sun et al. Brain Targeting Bacterial Extracellular Vesicles Enhance Ischemic Stroke Therapy via Efficient ROS Elimination and Suppression of Immune Infiltration
Zhao et al. Reversing immune evasion using a DNA nano-orchestrator for pancreatic cancer immunotherapy
US20080063631A1 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2409960A1 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
CN112138018A (zh) 铁皮石斛多糖在制备靶向肿瘤相关巨噬细胞治疗肿瘤药物中的应用
HK1093428A (en) Apoptotic entities for use in treatment of t-cell-mediated und inflammatory disorders
HK1055079B (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
CN101686992A (zh) 卡介菌多糖核酸提取物在制备治疗变态反应性皮肤病的药物中的应用及其注射剂和制备方法
US20070298020A1 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2409992A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
Chandana Immunity and the role of selected plants as immunomodulators: a review
HK1055080B (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2409994A1 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
CN121041434A (zh) 一种包含聚唾液酸-蜂毒肽聚离子复合物和唾液酸修饰蒽环类抗肿瘤药物脂质体的药物组合物及其用途
CN102793690A (zh) 胡桃醌在制备治疗自身免疫及炎症性疾病药物方面的应用
DE2755802A1 (de) Verfahren zur herstellung von gamma-globulinen und immunnucleinsaeuren sowie immundialysaten und hierfuer verwendete mittel
Beeton preferential uptake of antioxidant carbon nanoparticles by t lymphocytes for immunomodulation

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees